Catalyst Pharmaceuticals (NASDAQ:CPRX) Director David Tierney Sells 26,000 Shares of Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director David Tierney sold 26,000 shares of the stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $20.20, for a total transaction of $525,200.00. Following the completion of the sale, the director directly owned 379,620 shares in the company, valued at approximately $7,668,324. This trade represents a 6.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Catalyst Pharmaceuticals Stock Up 0.9%

CPRX stock opened at $20.38 on Friday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.00 and a fifty-two week high of $26.58. The firm’s 50-day simple moving average is $21.06 and its 200 day simple moving average is $22.53. The stock has a market cap of $2.49 billion, a PE ratio of 12.35, a price-to-earnings-growth ratio of 0.82 and a beta of 0.70.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Thrivent Financial for Lutherans boosted its holdings in shares of Catalyst Pharmaceuticals by 2.4% in the second quarter. Thrivent Financial for Lutherans now owns 84,309 shares of the biopharmaceutical company’s stock worth $1,830,000 after buying an additional 1,957 shares during the period. State of Wyoming boosted its holdings in shares of Catalyst Pharmaceuticals by 43.6% in the second quarter. State of Wyoming now owns 18,155 shares of the biopharmaceutical company’s stock worth $394,000 after buying an additional 5,508 shares during the period. Nomura Holdings Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 321.3% in the second quarter. Nomura Holdings Inc. now owns 88,821 shares of the biopharmaceutical company’s stock worth $1,927,000 after buying an additional 67,738 shares during the period. Public Sector Pension Investment Board boosted its holdings in shares of Catalyst Pharmaceuticals by 13.5% in the second quarter. Public Sector Pension Investment Board now owns 466,402 shares of the biopharmaceutical company’s stock worth $10,121,000 after buying an additional 55,640 shares during the period. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in shares of Catalyst Pharmaceuticals by 4.7% in the second quarter. CANADA LIFE ASSURANCE Co now owns 127,700 shares of the biopharmaceutical company’s stock worth $2,772,000 after buying an additional 5,677 shares during the period. Institutional investors own 79.22% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, June 5th. Zacks Research cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Finally, Wall Street Zen cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, August 9th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $33.20.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.